›› 2018, Vol. 38 ›› Issue (11): 1396-.doi: 10.3969/j.issn.1674-8115.2018.11.023

• Review • Previous Articles    

Application of CRISPR-Cas9 technology in non-cancerous hematological disorders

WENG Zhen1, NIU Xiao-yin2, ZHOU Jun-song1   

  1. 1. Cyrus Tang Hematology Center, Soochow University, Suzhou 215123, China; 2. Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2018-11-28 Published:2018-12-15
  • Supported by:
    National Natural Science Foundation of China, 81700129, 81670133; Shanghai Municipal Commission of Health and Family Planning Research Project, 201640137

Abstract: The recent discovery of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) system for precise genome editing has revolutionized methodologies in hematology studies. CRISPR-Cas9 technology can remove and correct genes or mutations, and introduce site-specific therapeutic genes in human cells. Therefore, it has become the ideal targets for inherited haematological disorders and could be the choice to alleviate disease-related symptomscorrecting disease-causing mutations in the near future. Prior to the of CRISPR-Cas9-mediated gene correction in humans, appropriate delivery systems with high efficiency and specificity must be identified, and ethical guidelines for applying the technology with controllable safety must be established. In this review, the latest applications of CRISPR-Cas9 technology in haematological disorders, current challenges and future directions were discussed.

Key words: CRISPR-Cas9, genome editing, non-cancerous hematological disorder, application

CLC Number: